Lean team, high stakes: Taking greater control of patient enrollment
Connecting site selection, forecasting and adaptation in one planning process
Midsize and emerging biopharma companies now drive a growing share of the industry’s R&D pipeline. Yet their clinical teams often plan trials with fewer feasibility resources and less internal trial history than large sponsors, while the enrollment stakes are just as high.
In this Applied Clinical Trials webcast, Harini Lakshminarayanan, Jennifer Baltzell and Maria Kliatchko of ZS follow an illustrative phase 3 non-small cell lung cancer trial in ZAIDYN® Clinical. They show how a connected data foundation and AI-enabled workflows can help lean teams choose sites, build forecasts they can defend and adjust course before timelines slip, while working more closely with contract research organization (CRO) partners.
You will learn:
- Why treating site selection, forecasting and adaptation as one connected process gives lean teams more control in CRO partnerships
- How an AI agent can read a protocol, find comparator trials and help narrow about 1,200 candidate sites to a shortlist of 120 across eight countries
- How a forecast built on site-level data replaces a single number with an enrollment curve and confidence bands, with reruns that take minutes instead of days
- How small gains across a representative five-study portfolio could add up to an estimated $20 million in savings and protected timeline value
Prefer to read? In this article, Harini Lakshminarayanan, Jennifer Baltzell and Maria Kliatchko of ZS lay out a connected approach to site selection, enrollment forecasting and course correction, with an illustrative phase 3 trial and its impact across a representative portfolio.